IGC Pharma (NYSEAMERICAN:IGC) Earns Sell Rating from Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of IGC Pharma (NYSEAMERICAN:IGC) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the construction company’s stock.

IGC Pharma Stock Down 6.3 %

Shares of IGC opened at $0.51 on Tuesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.86 and a current ratio of 1.85. IGC Pharma has a twelve month low of $0.25 and a twelve month high of $0.91. The company has a market capitalization of $33.94 million, a price-to-earnings ratio of -1.95 and a beta of 1.71.

IGC Pharma (NYSEAMERICAN:IGC) last posted its quarterly earnings data on Wednesday, February 14th. The construction company reported ($0.09) EPS for the quarter. IGC Pharma had a negative net margin of 1,163.24% and a negative return on equity of 110.37%. The company had revenue of $0.20 million during the quarter.

Institutional Trading of IGC Pharma

An institutional investor recently raised its position in IGC Pharma stock. Commonwealth Equity Services LLC increased its stake in shares of IGC Pharma, Inc. (NYSEAMERICAN:IGC) by 211.3% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 165,490 shares of the construction company’s stock after acquiring an additional 112,334 shares during the period. Commonwealth Equity Services LLC owned about 0.31% of IGC Pharma worth $59,000 as of its most recent filing with the SEC. 3.87% of the stock is currently owned by institutional investors and hedge funds.

IGC Pharma Company Profile

IGC Pharma, Inc, a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development.